Development of an osmoprotective microemulsion as a therapeutic platform for ocular surface protection.
Hyperosmolar model
In vivo tolerance
Ocular drug delivery
Ophthalmic microemulsions
Osmoprotection
Stability
Journal
International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127
Informations de publication
Date de publication:
25 Jul 2022
25 Jul 2022
Historique:
received:
27
03
2022
revised:
03
06
2022
accepted:
19
06
2022
pubmed:
26
6
2022
medline:
14
7
2022
entrez:
25
6
2022
Statut:
ppublish
Résumé
Self-emulsified osmoprotective ophthalmic microemulsions (O/A) were prepared by combining betaine/leucine, clusterin/oleanolic acid, and hyaluronic acid or Dextran. The microemulsions contained an internal oily phase (1.2%), an external aqueous phase (96.3%), cosolvents (1%), and surfactants (1.5%). Physicochemical characterization and in vivo and in vitro tolerance were analyzed. The formulations' osmoprotective in vitro activity was assayed in a hyperosmolar model in human corneal cells. Average internal phase sizes were 16-26 nm for the microemulsions including Dextran. Addition of hyaluronic acid increased the size range (25-39 nm). Addition of osmoprotectants did not change nanodroplet size. The formulations were isotonic (280-290 mOsm/L) with neutral pH (≈7) and zeta potential (-10 to 0 mV), low surface tension (≈35-40mN·m
Identifiants
pubmed: 35752388
pii: S0378-5173(22)00503-8
doi: 10.1016/j.ijpharm.2022.121948
pii:
doi:
Substances chimiques
Dextrans
0
Emulsions
0
Surface-Active Agents
0
Hyaluronic Acid
9004-61-9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
121948Informations de copyright
Copyright © 2022. Published by Elsevier B.V.